KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Total Current Liabilities (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Total Current Liabilities for 7 consecutive years, with $246.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 98.54% to $246.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $246.0 million through Dec 2025, up 98.54% year-over-year, with the annual reading at $246.0 million for FY2025, 98.54% up from the prior year.
  • Total Current Liabilities hit $246.0 million in Q4 2025 for GoodRx Holdings, up from $181.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $246.0 million in Q4 2025 to a low of $59.4 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $104.7 million across 5 years, with a median of $93.7 million in 2022.
  • Biggest YoY gain for Total Current Liabilities was 98.54% in 2025; the steepest drop was 11.28% in 2025.
  • Year by year, Total Current Liabilities stood at $81.1 million in 2021, then fell by 5.91% to $76.3 million in 2022, then soared by 60.59% to $122.6 million in 2023, then rose by 1.1% to $123.9 million in 2024, then surged by 98.54% to $246.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for GDRX at $246.0 million in Q4 2025, $181.9 million in Q3 2025, and $130.9 million in Q2 2025.